检索结果-南通市图书馆

Efficacy and safety of Tianqi Pingchan Granule, a compound Chinese herbal medicine, for levodopa-induced dyskinesia in Parkinson's disease:A randomized double-blind placebo-controlled trial

在线全文

学校读者我要写书评

暂无评论

Journal of Integrative Medicine 2024年第05期 545-551页

作者： Yu Zhang xiao-bo Zhu yang zhao Gui-yun cui Wen-tao li Can-xing Yuan Jian-ping Huang Ying Wan Na Wu lu Song Jia-hao zhao yan liang Chuan-ying Xu mei-juan liu chen Gao Xin-xin chen Zhen-guo liu Department of Neurology Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine Department of Neurology Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine Parkinson's Disease Center the Affiliated Hospital of Xuzhou Medical University Department of Neurology Shanghai Municipal Hospital of Traditional Chinese Medicine Affiliated to Shanghai University of Traditional Chinese Medicine Department of Neurology Longhua HospitalShanghai University of Traditional Chinese Medicine Department of Neurology Wenzhou Central Hospital

Background: Patients with Parkinson's disease(PD) undergoing long-term levodopa therapy are prone to develop levodopa-induced dyskinesia(liD). Amantadine is the main drug recommended for the treatment of liD by current guidelines, but it is far from meeting clinical needs. Tianqi Pingchan Granule(TPG), a compound Chinese herbal medicine, has been developed to relieve symptom of ***: This randomized controlled trial evaluated the efficacy and safety of the combination of TPG and amantadine for ***, setting, participants and interventions: This is a randomized double-blind placebo-controlled trial,conducted from January 2020 to August 2021 at 6 sites in Jiangsu, Zhejiang and Shanghai, China. One hundred PD patients with ≥ 0.5 h of liD were randomly assigned to either the TPG plus amantadine group(TPG group) or the placebo plus amantadine group(placebo group), and treated for a period of12 weeks. To ensure unbiased results, all study participants, investigators and sponsors were unaware of group allocations. Additionally, the data analysts remained blinded until the analysis was *** outcome measures: The primary outcome was assessed using the Unified Dyskinesia Rating Scale(UDysRS)(Range 0–104). The key secondary end point was improvement of motor and non-motor symptoms. Safety analyses included all enrolled ***: One hundred patients were enrolled and randomized into the two treatment groups. The changes in UDysRS at week 12 were –11.02 for the TPG group and –4.19 for the placebo group(treatment difference –6.83 [–10.53 to –3.12]; P = 0.0004). Adverse events were reported for 2 of 50 patients(4.0%) in each of the ***: This study indicated that a 12-week treatment of amantadine plus TPG effectively reduced UDysRS scores and was well tolerated, demonstrating the efficacy and safety of TPG for the treatment of liD in PD.

关键词：

CEPC Technical Design Report

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

Radiation Detection Technology and Methods 2024年第1期8卷 I0003-I0016,1-1091页

作者： Waleed Abdallah Tiago Carlos Adorno de Freitas Konstantin Afanaciev Shakeel Ahmad Ijaz Ahmed xiaocong Ai Abid Aleem Wolfgang Altmannshofer Fabio Alves Weiming An rui An Daniele Paolo Anderle Stefan Antusch yasuo Arai Andrej Arbuzov Abdesslam Arhrib Mustafa Ashry Sha Bai Yu Bai yang Bai Vipul Bairathi Csaba Balazs Philip Bambade Yong Ban Tripamo Bandyopadhyay Shou-Shan Bao Desmond P.Barber Ayse Bat Varvara Batozskaya Subash Chandra Behera Alexander Belyaev Michele Bertucci xiao-jun Bi Yuanjie Bi Tianjian Bian Fabrizio Bianchi Thomas Biekotter Michela Biglietti Shalva Bilanishvili Deng Binglin Denis Bodrov Anton Bogomyagkov Serge Bondarenko Stewart Boogert Maarten Boonekamp Marcello Borri Angelo Bosotti Vincent Boudry Mohammed Boukidi Igor Boyko Ivanka Bozovic Giuseppe Bozzi Jean-Claude Brient Anastasiia Budzinskaya Masroor Bukhari Vladimir Bytev Giacomo Cacciapaglia Hua Cai Wenyong Cai Wujun Cai Yijian Cai Yizhou Cai Yuchen Cai Haiying Cai Huacheng Cai Lorenzo Calibbi junsong Cang Guofu Cao Jianshe Cao Antoine Chance xuejun Chang Yue Chang Zhe Chang Xinyuan Chang Wei Chao Auttakit Chatrabhuti Yimin Che Yuzhi Che Bin chen Danping chen Fuqing chen Fusan chen Gang chen Guoming chen Hua-Xing chen Huirun chen Jinhui chen Ji-Yuan chen Kai chen Mali chen mingjun chen mingshui chen Ning chen Shanhong chen Shanzhen chen Shao-Long chen Shaomin chen Shiqiang chen Tianlu chen Wei chen Xiang chen xiaoyu chen Xin chen Xun chen Xurong chen Ye chen Ying chen Yukai chen Zelin chen Zilin chen Gang chen Boping chen Chunhui chen Hok Chuen cheng Huajie cheng Shan cheng Tongguang cheng Yunlong Chi Pietro Chimenti Wen Han Chiu Guk Cho ming-Chung Chu xiaotong Chu Ziliang Chu Guglielmo Coloretti Andreas Crivellin Hanhua cui xiaohao cui zhaoyuan cui Brunella D'Anzi ling-Yun Dai Xinchen Dai Xuwen Dai Antonio De Maria Nicola De Filippis Christophe De La Taille Francesca De Mori Chiara De Sio Elisa Del Core Shuangxue Deng Wei-Tian Deng Zhi Deng Ziyan Deng Bhupal Dev Tang Dewen Biagio Di Micco Ran Ding Siqin Dingl yadong Ding Haiyi Dong Jianin AGH University of Science and Technology Faculty of Physics and Applied Computer ScienceKrakow Anhui University HefeiAnhui Applied Physics Department Federal Urdu University of ArtsScience and TechnologyIslamabad Banaras Hindu University Institute of ScienceVaranasi Bandirma Onyedi Eylul University Bandirma Beihang University Beijing Beijing Computational Science Research Center Beijing Beijing Conveyi LTD Beijing Beijing Glass Research Institute Co. LtdBeijing Beijing Institute of Technology Beijing Beijing Normal University Beijing Brown University ProvidenceRI Budker Institute of Nuclear Physics Novosibirsk Cadi Ayyad University Laboratory of Fundamental and Applied PhysicsPolydisciplinary FacultyMarrakech Cairo University Giza Center for Theory and Computation National Tsing Hua UniversityHsinchu Central China Normal University WuhanHubei Central South University ChangshaHunan Centro de Fisica Teorica de Particulas Universidade Tecnica de LisboaLisboa chengdu KaitengSifang Digital Radio&TV Equipment Co. LtdChengduSichuan China academy of engineering physics MianyangSichuan China building materials academy Beijing China Center of Advanced Science and Technology Beijing China Institute of Atomic Energy Beijing China Jiliang University HangzhouZhejiang China Nuclear Instrument CO. LTDBeijing China University of Geosciences Beijing China University of Geosciences WuhanHubei China University of Mining and Technology XuzhouJiangsu China West Normal University NanchongSichuan Chongqing University Department of PhysicsChongqing Chulalongkorn University Bangkok City University of Hong Kong Department of PhysicsHong Kong Cockcroft Institute Daresbury Cornell University IthacaNY CPPM(AMU/IPhU&CNRS/INP) Marseille Dalian Minzu University DalianLiaoning Dalian University of Technology Department of PhysicsDalian Deutsches Elektronen-Synchrotron DESY Hamburg Dzhelepov Laboratory of Nuclear Problems of Joint Institute for Nuclear Research(DLNP JINR) Dubna East China University Of Science And Technol

The Circular Electron Positron Collider(CEPC)is a large scientific project initiated and hosted by China,fostered through extensive collaboration with international *** complex comprises four accelerators:a 30 GeV linac,a 1.1 GeV Damping Ring,a Booster capable of achieving energies up to 180 GeV,and a Collider operating at varying energy modes(Z,W,H,and tt).The linac and Damping Ring are situated on the surface,while the subterranean Booster and Collider are housed in a 100 km circumference underground tunnel,strategically accommodating future expansion with provisions for a potential Super Proton Proton Collider(SPPC).The CEPC primarily serves as a Higgs *** its baseline design with synchrotron radiation(SR)power of 30 MW per beam,it can achieve a luminosity of 5×10^(34)cm^(-2)s^(-1)per interaction point(IP),resulting in an integrated luminosity of 13 ab^(-1)for two IPs over a decade,producing 2.6 million Higgs *** the SR power to 50 MW per beam expands the CEPC's capability to generate 4.3 million Higgs bosons,facilitating precise measurements of Higgs coupling at sub-percent levels,exceeding the precision expected from the HL-LHC by an order of *** Technical Design Report(TDR)follows the Preliminary Conceptual Design Report(Pre-CDR,2015)and the Conceptual Design Report(CDR,2018),comprehensively detailing the machine's layout,performance metrics,physical design and analysis,technical systems design,R&D and prototyping efforts,and associated civil engineering ***,it includes a cost estimate and a preliminary construction timeline,establishing a framework for forthcoming engineering design phase and site selection *** is anticipated to begin around 2027-2028,pending government approval,with an estimated duration of 8 *** commencement of experiments and data collection could potentially be initiated in the mid-2030s.

关键词： initiated exceeding precise

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

CaF_2渣系失重与成分变化的试验研究

钢铁研究学报 2010年第12期22卷 11-13,43页

作者：陈艳梅赵俊学路晓涛崔雅茹李小明樊君西安建筑科技大学冶金工程学院陕西西安710055

针对ANF-6渣应用过程演化而成的CaF2-CaO-Al2O3-SiO2-MgO渣系,通过测定炉渣的失重量,建立二次回归正交设计模型,借此研究了熔渣的失重率与CaF2、CaO、Al2O3、SiO2和MgO含量的关系。结果表明:w(CaF2)由50%增加到65%,失重率大约升高6%,而... 详细信息

针对ANF-6渣应用过程演化而成的CaF2-CaO-Al2O3-SiO2-MgO渣系,通过测定炉渣的失重量,建立二次回归正交设计模型,借此研究了熔渣的失重率与CaF2、CaO、Al2O3、SiO2和MgO含量的关系。结果表明:w(CaF2)由50%增加到65%,失重率大约升高6%,而且在相同的试验条件下,SiO2、Al2O3和MgO均可提高渣系的失重率,但随之CaO含量的增加,熔渣的失重率降低。此外,CaF2-Al2O3-CaO-SiO2-MgO渣系在熔点附近由于渣系中氧化物与氟化物发生反应,造成炉渣急剧失重,导致氟化钙渣系成分不断发生变化。

关键词：氟化钙渣系失重率二次回归正交设计

基于白光中子源的^(197)Au中子辐射俘获截面测量及共振参数分析

在线全文

学校读者我要写书评

暂无评论

物理学报 2024年第7期73卷 104-113页

作者：罗淏天张奇玮栾广源王晓宇邹翀任杰阮锡超贺国珠鲍杰孙琪黄翰雄王朝辉吴鸿毅顾旻皓余滔解立坤陈永浩安琪白怀勇鲍煜曹平陈昊磊陈琪萍陈裕凯陈朕崔增琪樊瑞睿封常青高可庆韩长材韩子杰何泳成洪杨黄蔚玲黄锡汝季筱璐吉旭阳蒋伟江浩雨姜智杰敬罕涛康玲康明涛李波李超李嘉雯李论李强李晓李样刘荣刘树彬刘星言穆奇丽宁常军齐斌斌任智洲宋英鹏宋朝晖孙虹孙康孙晓阳孙志嘉谭志新唐洪庆唐靖宇唐新懿田斌斌王丽娇王鹏程王琦王涛峰文杰温中伟吴青彪吴晓光吴煊羊奕伟易晗于莉于永积张国辉张林浩张显鹏张玉亮张志永赵豫斌周路平周祖英朱丹阳朱科军朱鹏朱兴华中国原子能科学研究院核数据重点实验室北京102413 中国科学院高能物理研究所北京100049 散裂中子源科学中心东莞523803 核探测与核电子学国家重点实验室北京100049 中国科学技术大学近代物理系核探测与核电子学国家重点实验室合肥230026 北京大学物理学院核物理与核技术国家重点实验室北京100871 中国工程物理研究院核物理与化学研究所绵阳621900 西北核技术研究院西安710024 中国科学院大学北京100049 中国科学技术大学工程与应用物理系合肥230026 北京航空航天大学物理学院北京100083 华能山东石岛湾核电有限公司荣成264312

中子辐射俘获反应在反应堆运行、核装置设计及核天体物理研究中起重要的作用.4πBaF_(2)探测装置有着高时间分辨能力、低中子灵敏度、高探测效率等优点,适合开展中子辐射俘获反应截面数据的测量.中国原子能科学研究院核数据重点实验室... 详细信息

中子辐射俘获反应在反应堆运行、核装置设计及核天体物理研究中起重要的作用.4πBaF_(2)探测装置有着高时间分辨能力、低中子灵敏度、高探测效率等优点,适合开展中子辐射俘获反应截面数据的测量.中国原子能科学研究院核数据重点实验室建立了伽马全吸收装置(Gamma total absorption facility,GTAF),该装置用28块六棱BaF_(2)晶体和12块五棱BaF_(2)晶体构成了外径25 cm,内径10 cm的球壳,覆盖了95.2%的立体角.利用GTAF在中国散裂中子源Back-n束线上,测量了197Au(n,γ)的反应截面数据.测量数据通过能量筛选、PSD方法、晶体多重性筛选进行了初步本底扣除,随后结合对^(nat)C及空样品的测量数据对本底进行了分析及扣除,获得了197Au俘获反应的产额,利用SAMMY程序拟合得到了^(197)Au在1—100 e V的共振能量、中子共振宽度和伽马共振宽度参数.实验测量结果与ENDF/B-VIII.0数据库符合良好,其共振参数存在一定差异,分析原因可能与GTAF能量分辨率、Back-n的中子能谱测量精度、以及实验本底扣除方法相关,这也是下一步工作的重点.

关键词：中子辐射俘获截面共振参数白光中子源伽马全吸收装置

维普期刊数据库博看期刊

Proportion of Uterine Malignant Tumors in Patients with Laparoscopic Myomectomy： A National Multicenter Study in China

在线全文

学校读者我要写书评

暂无评论

Chinese Medical Journal 2017年第22期130卷 2661-2665页

作者： Hua yang xiao-Chuan li chen yao Jing-He Lang Hang-mei Jin ming-Rong Xi Gang Wang lu-Wen Wang Min Hao yan Ding Jie chen Jian-Qing Zhang lu Han cheng-Xiu Guo Xiang xue yan li Jian-Hua Zheng Man-Hua cui Huai-Fang li Guang-Shi tao Long chen Su-Min Wang An-Wei lu Ze-Hua Huang Qing liu ya-li Zhuang Xiang-Hua Huang Gen-Hai Zhu Ou-Ping Huang li-Na Hu Mu-jun li Hong-lin Zhou Jing-Hui Song Lan Zhu Department of Obstetrics and Gynecology Peking Union Medical College Hospital Beijing 100730 China Department of Biostatistics Peking University Clinical Research Institute Peking University First Hospital Beijing 100871 China Department of Obstetrics and Gynecology Zhejiang University Affiliated Obstetrics and Gynecology Hospital Zhejiang Hangzhou 310006 China Department of Obstetrics and Gynecology West China Second Hospital of Sichuan University Cbengdu Sichuan 610041 China Department of Obstetrics and Gynecology The First People's Hospital of Foshan City Foshan Guangdong 528010 China Department of Obstetrics and Gynecology Maternal and Child Health Hospital of Henan Province Zhengzhou Henan 450052 China Department of Obstetrics and Gynecology The Second Hospital of Shanxi Medical University Datong Shanxi 030001 China Department of Obstetrics and Gynecology The First Affiliated Hospital of Xinjiang Medical University Urumchi Xinjiang 830000 China Department of Obstetrics and Gynecology People's Hospital of Fujian Province Fuzhou Fujian 350000 China Department of Obstetrics and Gynecology Qinghai Red Cross Hospital Xining Qinghai 810000 China Department of Obstetrics and Gynecology Dalian Maternity Hospital Dalian Liaoning 116021 China Department of Obstetrics and Gynecology Tianjin Central Maternity Hospital Tianjin 300100 China Department of Obstetrics and Gynecology The Second Affiliated Hospital of Xi'an Jiaotong University Xi'an Shaanxi 710061 China Department of Obstetrics and Gynecology General Hospital of Ningxia Medical University Yinchuan Ningxia Hui Autonomous Region 750003 China Department of Obstetrics and Gynecology The First Affiliated Hospital of Harbin Medical University Harbin Heilongjiang 150007 China Department of Obstetrics and Gynecology The Second Hospital of Jilin University Changchun Jilin 130041 China Department of Obstetrics and Gynecology Shanghai Tongji Hospital Shanghai 200065 China Department of Obstetrics and Gynec

Background： The Food and Drug Administration recently announced that the use of morcellation may cause fibroids or pelvic dissemination and metastasis of uterine sarcoma; therefore, the use of morcellation is limited in the USA. A large sample study is necessary to assess the proportion of uterine malignant tumors found in patients with laparoscopic myomectomy. Methods： A national multicenter study was performed in China. From 2002 to 2014, 33,723 cases were retrospectively selected. We calculated the prevalence and recorded the clinical characteristics of the patients with malignancy after morcellation application. A total of 62 cases were finally pathologically confirmed as malignant postoperatively. Additionally, the medical records of the 62 patients were analyzed in details. Results： The proportion of postoperative malignancy after morcellation application was 0.18% （62/33,723） for patients who underwent laparoscopic myomectomy. Nearly 62.9% （39/62） of patients had demonstrated blood flow signals in the uterine fibroids before surgery. And, 23 （37.1%） patients showed rapid growth at the final preoperative ultrasound. With respect to the pathological types, 38 （61.3%） patients had detectable endometrial stromal sarcoma, 13 （21.0%） had detectable uterine leiomyosarcoma, only 3 （3.2%） had detectable carcinosarcoma, and 5 （8.1%） patients with leiomyoma had an undetermined malignant potential. Conclusions： The proportion of malignancy is low after using moreellation in patients who undergo laparoscopie myomectomy. Patients with fast-growing uterine fibroids and abnormal ultrasonic tumor blood flow should be considered for malignant potential, and morcellation should be avoided.

关键词： Laparoscopic Myomectomy Morcellation Sarcoma

Delivery room resuscitation and short-term outcomes of extremely preterm and extremely low birth weight infants: a multicenter survey in North China

在线全文

学校读者我要写书评

暂无评论

Chinese Medical Journal 2021年第13期134卷 1561-1568页

作者： Shuai-jun li Qi Feng Xiu-Ying Tian Ying Zhou Yong Ji Yue-mei li Shu-Fen Zhai Wei Guo Fang Zhang Rong-Xiu Zheng Hai-Ying He Xia liu jun-Yi Wang Hua mei Hong-Yun Wang Hua Xie Chao-mei Zeng li Ma Ping-Ping Zhang Jin-Yu li xiao-Ying Wang li-Hua li Hong cui Shu-Lan yang lu chen xiao-Hong Gu yan-Ju Hu Sheng-Shun Que li-Xia Sun ming yang Wen-li zhao Qiu-yan Ma Hai-Juan Wang Jiu-Ye Guo Department of Pediatrics Peking University First HospitalBeijing 100034China Department of Neonatology Tianjin Central Hospital of Gynecology ObstetricsTianjin 300100China Department of Pediatrics Peking University Third HospitalBeijing 100191China Neonatal Intensive Care Unit Children's Hospital of ShanxiTaiyuanShanxi 030031China Department of Neonatology The Second Hospital of Hebei Medical UniversityShijiazhuangHebei 050000China Department of Neonatology Handan Central HospitalHandanHebei 056004China Department of Neonatology Xingtai People's HospitalXingtaiHebei 054031China Department of Neonatology Tangshan Maternal and Child Health HospitalTangshanHebei 071023China Department of Pediatrics Tianjin Medical University General HospitalTianjin 300052China Department of Pediatrics Baogang Third Hospital of HongCi GroupBaotouInner Mongolia Autonomous Region 014010China Department of Neonatology Affiliated Hospital of Chengde Medical UniversityChengdeHebei 067000China Department of Pediatrics The First Hospital of Tsinghua UniversityBeijing 100016China Department of Neonatology The Affiliated Hospital of Inner Mongolia Medical UniversityHohhotInner Mongolia Autonomous Region 010050China Department of Neonatology Inner Mongolia Maternal and Child Health HospitalHohhotInner Mongolia Autonomous Region 010020China Department of Neonatology Affiliated Hospital of Chifeng UniversityChifengInner Mongolia Autonomous Region 024005China Department of Pediatrics Peking University People's HospitalBeijing 100044China Department of Neonatology Hebei Children's HospitalShijiazhuangHebei 050000China Department of Neonatology Tianjin First Central HospitalTianjin 300384China Department of Pediatrics Peking Union Medical College HospitalBeijing 100730China Department of Neonatology Children's Hospital Capital Institute of PediatricsBeijing 100020China Department of Pediatrics Beijing Luhe Hospital.Capital Medical UniversityBeijing 101149China Department of Pediatrics Beijing Fri

Background:Delivery room resuscitation assists preterm infants,especially extremely preterm infants(EPI)and extremely low birth weight infants(ELBWI),in breathing support,while it potentially exerts a negative impact on the lungs and outcomes of preterm *** study aimed to assess delivery room resuscitation and discharge outcomes of EPI and ELBWI in ***:The clinical data of EPI(gestational age[GA]livery room resuscitation and risk factors for delivery room intubation(DRI).The secondary outcomes were survival rates,incidence of bronchopulmonary dysplasia(BPD),and risk factors for ***:A cohort of 952 preterm infants were *** incidence of DRI,chest compressions,and administration of epinephrine was 55.9%(532/952),12.5%(119/952),and 7.0%(67/952),*** analysis revealed that the risk factors for DRI were GAlivery room(OR,0.273;95%CI,0.160–0.467)were preventive factors for BPD(all Plusion:Improving delivery room resuscitation and management of respiratory complications are imperative during early management of the health of EPI and

关键词： Extremely preterm Extremely low birth weight infants Delivery room resuscitation Survival rate BPD Risk factors

Chemoprophylaxis, diagnosis, treatments, and discharge management of COVID-19: An evidence-based clinical practice guideline(updated version)

在线全文

学校读者我要写书评

暂无评论

Military Medical Research 2020年第3期7卷 249-282页

作者： Ying-Hui Jin Qing-Yuan Zhan Zhi-Yong Peng xue-Qun Ren Xun-tao Yin lin Cai Yu-Feng Yuan Ji-Rong Yue xiao-Chun Zhang Qi-Wen yang Jianguang Ji Jian Xia Yi-Rong li Fu-Xiang Zhou ya-Dong Gao Zhui Yu Feng Xu ming-li Tu li-ming Tan Min yang Fang chen xiao-Ju Zhang mei Zeng Yu Zhu Xin-Can liu Jian yang Dong-Chi zhao Yu-Feng Ding Ning Hou Fu-Bing Wang Hao chen Yong-Gang Zhang Wei li Wen chen Yue-Xian Shi Xiu-Zhi yang xue-jun Wang yan-jun Zhong ming-Juan zhao Bing-Hui li lin-lu Ma Hao Zi Na Wang Yun-Yun Wang Shao-Fu Yu lu-yao li Qiao Huang Hong Weng Xiang-Ying Ren li-Sha luo Man-ru Fan Di Huang Hong-yang xue lin-Xin Yu Jin-Ping Gao Tong Deng Xian-tao Zeng Hong-jun li Zhen-Shun cheng xiao-mei yao Xing-Huan Wang Center for Evidence-Based and Translational Medicine Zhongnan Hospital of Wuhan UniversityWuhan 430071China National Clinical Research Center for Respiratory Diseases China-Japan Friendship HospitalBeijing 100029China Department of Pulmonary and Critical Care Medicine China-Japan Friendship HospitalBeijing 10029China Leishenshan Hospital in Wuhan Wuhan 430200China Department of Critical Care Medicine Zhongnan Hospital of Wuhan UniversityWuhan 430071China Institutes of Evidence-based Medicine and Knowledge Translation Henan UniversityKaifeng 475000HenanChina Department of Medical Imaging Guizhou Provincial People’s HospitalGuiyang 550002China Departments of Orthopedics Zhongnan Hospital of Wuhan UniversityWuhan 430071China Department of Hepatobiliary Surgery Zhongnan Hospital of Wuhan UniversityWuhan 430071China National Clinical Research Center for Geriatrics West China Hospital of Sichuan UniversityChengdu 610041China Department of Geriatrics West China Hospital of Sichuan UniversityChengdu 610041China Department of Radiology Zhongnan Hospital of Wuhan UniversityWuhan 430071China Department of Clinical Laboratory Peking Union Medical College Hospital(PUMCH)Peking Union Medical CollegeChinese Academy of Medical Sciences(CAMS)Beijing 100730China Center for Primary Health Care Research Lund University and Region Skåne25002 MalmöSweden Emergency Center Zhongnan Hospital of Wuhan UniversityWuhan 403371China Department of Allergology Zhongnan Hospital of Wuhan UniversityWuhan 430071China Department of Radiation and Medical Oncology Zhongnan Hospital of Wuhan UniversityWuhan 43071China Department of Critical Care Medicine Renmin Hospital of Wuhan UniversityWuhan 430060China Department of Emergency Medicine and Chest Pain Center Qilu Hospital of Shandong UniversityJinan 250002China Department of Respiratory and Critical Care Medicine Suizhou Central HospitalHubei University of MedicineSuizhou 441300HubeiChina Department of Clinic Pharmacy Second People’s Hospital of Huaihua Ci

The novel severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)is the cause of a rapidly spreading illness,coronavirus disease 2019(COVID-19),affecting more than seventeen million people around the *** and treatment guidelines for clinicians caring for patients are *** the early stage,we have issued"A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus(2019-nCoV)infected pneumonia(standard version)";now there are many direct evidences emerged and may change some of previous recommendations and it is ripe for develop an evidence-based *** formed a working group of clinical experts and *** steering group members proposed 29 questions that are relevant to the management of COVID-19 covering the following areas:chemoprophylaxis,diagnosis,treatments,and discharge *** searched the literature for direct evidence on the management of COVID-19,and assessed its certainty generated recommendations using the Grading of Recommendations,Assessment,Development and Evaluation(GRADE)*** were either strong or weak,or in the form of ungraded consensus-based ***,we issued 34 *** them,6 were strong recommendations for,14 were weak recommendations for,3 were weak recommendations against and 11 were ungraded consensus-based *** covered topics of chemoprophylaxis(including agents and Traditional Chinese Medicine(TCM)agents),diagnosis(including clinical manifestations,reverse transcription-polymerase chain reaction(RT-PCR),respiratory tract specimens,IgM and IgG antibody tests,chest computed tomography,chest X-ray,and CT features of asymptomatic infections),treatments(including lopinavirritonavir,umifenovir,favipiravir,interferon,remdesivir,combination of antiviral drugs,hydroxychloroquine/chloroquine,interleukin-6 inhibitors,interleukin-1 inhibitors,glucocorticoid,qingfei paidu decoction,lianhua qingwen granules/capsules,convalescent plasma,lung

关键词： COVID-19 SARS-CoV-2 Recommendation Chemoprophylaxis Diagnosis Treatment Discharge management Traditional Chinese medicine guideline

Efficacy and Safety of Niaoduqing Particles for Delaying Moderate-to-severe Renal Dysfunction： A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Study

在线全文

学校读者我要写书评

暂无评论

Chinese Medical Journal 2017年第20期130卷 2402-2409页

作者： Ying Zheng Guang-yan Cai li-Qun He Hong-li lin xiao-Hong cheng Nian-Song Wang Gui-Hua Jian Xu-Sheng liu Yu-Ning liu zhao-Hui Ni Jing-Ai Fang Han-lu Ding Wang Guo ya-Ni He li-Hua Wang ya-Ping Wang Hong-tao yang Zhi-ming Ye Ren-Huan YU li-Juan zhao Wen-Hua Zhou Wen-Ge li Hui-Juan Mao Yong-li Zhan zhao Hu chen yao Ri-Bao Wei Xiang-mei chen Department of Nephrology Chinese People's Liberation Army General Hospital Chinese People's Liberation Army Institute of Nephrology State Key Laboratory of Kidney Diseases (2011DAVO0088) National Clinical Research Center for Kidney Diseases Beijing 100853 China Department of Nephrology Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine Shanghai 200021 China Department of Nephrology First Affiliated Hospital of Dalian Medical University Dalian Liaoning 116011 China Department of Nephrology Shaanxi Traditional Chinese Medicine Hospital Xi'an Shaanxi 710003 China Department of Nephrology and Rheumatology Affiliated Sixth People's Hospital Shanghai Jiao Tong University Shanghai 200233 China Department of Nephrology Guangdong Provincial Hospital of Chinese Medicine Guangzhou Guangdong 510120 China Department of Nephrology Dongzhimen Hospital The First Affiliated Hospital of Beijing University of Chinese Medicine Beijing 100700 China Department of Nephrology Renji Hospital Shanghai Jiao Tong University Shanghai 200127 China Department of Nephrology First Affiliated Hospital of Shanxi Medical University Taiyuan Shanxi 030001 China Department of Nephrology University of Electronic Science and Technology Sichuan Academy of Sciences and Sichuan Provincial People's Hospital Chengdu Sichuan 610072 China Department of Nephrology Beijing Friendship Hospital Capital Medical University Beijing 100050 China Department of Nephrology Daping Hospital Third Military Medical University Chongqing 400042 China Department of Nephrology Second Affiliated Hospital of Shanxi Medical University Taiyuan Shanxi 030001 China Department of Nephrology Army General Hospital Beijing 100700 China Department of Nephrology First Teaching Hospital of Tianjin University of Traditional Chinese Medicine Tiaojin 300192 China Department of Nephrology Guangdong General Hospital Guangdong Academy of Medical Sciences Guangzhou Guangdong 510030 China Department o

Background： Chronic kidney disease （CKD） with moderate-to-severe renal dysfunction usually exhibits an irreversible course, and available treatments for delaying the progression to end-stage renal disease are limited. This study aimed to assess the efficacy and safety of the traditional Chinese medicine, Niaoduqing particles, for delaying renal dysfunction in patients with stage 3b-4 ***： The present study was a prospective, randomized, double-blind, placebo-controlled, naulticentcr clinical trial. Frorn May 2013 to December 2013,300 CKD patients with an estimated glomerular filtration rate （eGFR） between 20 and 45 ml ＂rain ~＂ 1.73 m 2, aged 18-70 years were recruited from 22 hospitals in 11 Chinese provinces. Patients were randomized in a 1：1 ratio to either a test group, which was administered Niaoduqing particles 5 g thrice daily and 10 g before bedtime for 24 weeks, or a control group, which was administered a placebo using the same methods. The primary endpoints were changes in baseline serum creatinine （Scr） and eGFR after completion of treatment. The primary endpoints were analyzed using Student＇s t-test or Wilcoxon＇s rank-sum test. The present study reported results based on an intention-to-treat （ITT） analysis. Results： A total of 292 participants underwent the ITT analysis. At 24 weeks, the median （interquartile range） change in Scr was 1.1 （-13.0-24.1） and 11.7 （-2.6-42.9） p, mol/L for the test and control groups, respectively （Z = 2.642, P = 0.008）, and the median change in eGFR was -0.2 （-4.3-2.7） and -2.2 （-5.7-0.8） ***-1·1.73 m-2, respectively （Z = -2.408, P = 0.016）. There were no significant differences in adverse events between the groups. Conclusions： Niaoduqing particles safely and effectively delayed CKD progression in patients with stage 3b-4 CKD. This traditional Chinese medicine may be a promising alternative medication for patients with moderate-to-severe renal dysfunction.

关键词： Chronic Kidney Disease Moderate-to-severe Renal Dysfunction Niaoduqing Particles Randomized Controlled Trial Traditional Chinese Medicine

Efficacy and safety of Shenyankangfu Tablet,a Chinese patent medicine,for primary glomerulonephritis:A multicenter randomized controlled trial

在线全文

学校读者我要写书评

暂无评论

Journal of Integrative Medicine 2021年第2期19卷 111-119页

作者： Jie Wu Shu-wei Duan Hong-tao yang Yue-yi Deng Wei li ya-ni He zhao-hui Ni Yong-li Zhan Shan lin Zhi-yong Guo jun Zhu Jing-ai Fang Xu-sheng liu li-hua Wang Rong Wang Nian-song Wang xiao-hong cheng li-qun He Ping luo Shi-ren Sun Ji-feng Sun Ai-ping Yin Geng-ru Jiang Hong-yu chen Wen-hu liu Hong-li lin Meng liang lu Ma ming chen li-qun Song Jian chen Qing Zhu Chang-ying Xing Yun li Ji-ning Gao Rong-shan li Ying li Hao Zhang Ying lu Qiao-ling Zhou jun-zhou Fu Qiang He Guang-yan Cai Xiang-mei chen Department of Nephrology Chinese People’s Liberation Army General HospitalChinese People’s Liberation Army Institute of NephrologyState Key Laboratory of Kidney Diseases(2011DAV00088)National Clinical Research Center for Kidney DiseasesBeijing 100853China Department of Nephrology First Teaching Hospital of Tianjin University of Traditional Chinese MedicineTianjin 300192China Department of Nephrology Longhua HospitalShanghai University of Traditional Chinese MedicineShanghai 200032China Department of Nephrology Shandong University of Traditional Chinese Medicine Affiliated HospitalJinan 250011.Shandong ProvinceChina Department of Nephrology Daping HospitalArmy Medical UniversityChongqing 400042China Department of Nephrology Renji HospitalShanghai Jiao Tong UniversityShanghai 200127China Department of Nephrology Guang’anmen HospitalChina Academy of Traditional Chinese Medical SciencesBeijing 100053China Department of Nephrology Tianjin Medical University General HospitalTianjin 300052China Department of Nephrology Changhai Hospital of ShanghaiNaval Medical UniversityShanghai 200433China Department of Nephrology West China HospitalChengdu 610083Sichuan ProvinceChina Department of Nephrology First Affiliated Hospital of Shanxi Medical UniversityTaiyuan 030001Shanxi ProvinceChina Department of Nephrology Guangdong Provincial Hospital of Chinese MedicineGuangzhou 510120Guangdong ProvinceChina Department of Nephrology Shanxi Medical University Second Affiliated HospitalTaiyuan 030001Shanxi ProvinceChina Department of Nephrology Shandong Provincial HospitalJinan 250021Shandong ProvinceChina Department of Nephrology and Rheumatology Affiliated Sixth People’s HospitalShanghai Jiao Tong UniversityShanghai 200233China Department of Nephrology Shaanxi Traditional Chinese Medicine HospitalXi'an 710003Shaanxi ProvinceChina Department of Nephrology Shuguang HospitalShanghai University of Traditional Chinese MedicineShanghai 200021China Department of Nephrology Jilin University Se

Background:Shenyankangfu Tablet(SYKFT)is a Chinese patent medicine that has been used widely to decrease proteinuria and the progression of chronic kidney ***:This trial compared the efficacy and safety of SYKFT,for the control of proteinuria in primary glomerulonephritis patients,against the standard drug,losartan ***,setting,participants and intervention:This was a multicenter,double-blind,randomized,controlled clinical *** glomerulonephritis patients,aged 18-70 years,with blood pressure≤140/90 mmHg,estimated glomerular filtration rate(eGFR)>45 mL/min per 1.73 ㎡,and 24-hour proteinuria level of 0.5-3.0 g,were recruited in 41 hospitals across 19 provinces in China and were randomly divided into five groups:SYKFT,losartan potassium 50 mg or 100 mg,SYKFT plus losartan potassium 50 mg or 100 *** outcome measu res:The primary outcome was change in the 24-hour proteinuria level,after 48 weeks of ***:A total of 735 participants were *** percent decline of urine protein quantification in the SYKFT group after 48 weeks was 8.78%±2.56%(P=0.006)more than that in the losartan 50 mg group,which was 0.51%±2.54%(P=1.000)less than that in the losartan 100 mg *** with the losartan potassium 50 mg group,the SYKFT plus losartan potassium 50 mg group had a 13.39%±2.49%(Plus losartan potassium 100 mg group had a 9.77%±2.52%(P=0.001)greater reduction in urine *** a superiority threshold of 15%,neither was statistically ***,serum creatinine and serum albumin from the baseline did not change statistically *** average change in TCM syndrome score between the patients who took SYKFT(-3.00[-6.00,-2.00])and who did not take SYKFT(-2.00[-5.00,0])was statistically significant(P=0.003).No obvious adverse reactions were observed in any ***:SYKFT decreased the proteinur

关键词： Herbal medicine,Chinese Shenyankangfu Tablet Primary glomerulonephritis Randomized controlled trial Double blind Double dummy